Literature DB >> 7606717

Mutation analysis of the BRCA1 gene in ovarian cancers.

H Takahashi1, K Behbakht, P E McGovern, H C Chiu, F J Couch, B L Weber, L S Friedman, M C King, M Furusato, V A LiVolsi.   

Abstract

Germline mutations of the BRCA1 tumor suppressor gene on chromosome 17q are involved in a significant fraction of hereditary breast and ovarian cancers. Allelic deletions that include the BRCA1 locus are common in breast and ovarian cancers, implying that somatic mutations of this gene may play an important role in the more common sporadic forms of these tumors as well. The recent cloning of BRCA1 allows direct testing of this hypothesis. A combination of single strand conformation and sequencing analyses was used to examine the 22 coding exons and intronic splice donor and acceptor regions of BRCA1 for mutations in 115 unselected cases of epithelial ovarian carcinoma. Seven mutations were identified, all of which were present in the germlines of patients with remarkable family or medical histories of breast and/or ovarian cancer. Eighty-nine of these tumors were examined for loss of heterozygosity in the BRCA1 region of chromosome 17q, and 67% of the tumors studied exhibited allelic deletions that included this region. These data are consistent with the hypothesis that BRCA1 mutations are involved in the etiology of hereditary ovarian carcinomas but occur rarely in sporadic tumors, and that the frequent allelic loss on chromosome 17q in this cancer type reflects the involvement of an additional tumor suppressor gene(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606717

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  BRCA1 and BRCA2 proteins: roles in health and disease.

Authors:  J A Duncan; J R Reeves; T G Cooke
Journal:  Mol Pathol       Date:  1998-10

Review 2.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

3.  Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

Authors:  F Durocher; P Tonin; D Shattuck-Eidens; M Skolnick; S A Narod; J Simard
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

4.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

5.  Germ-line BRCA1 mutations in selected men with prostate cancer.

Authors:  A A Langston; J L Stanford; K G Wicklund; J D Thompson; R G Blazej; E A Ostrander
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

6.  BRCA1 mutation update and analysis.

Authors:  K Grade; B Jandrig; S Scherneck
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

7.  The 12 base pair duplication/insertion alteration could be a regulatory mutation.

Authors:  M Robledo; A Osorio; C Sentís; J Albertos; L Estevez; J Benítez
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

8.  Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.

Authors:  Suhwan Chang; Kajal Biswas; Betty K Martin; Stacey Stauffer; Shyam K Sharan
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

9.  Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.

Authors:  S A Gayther; P Harrington; P Russell; G Kharkevich; R F Garkavtseva; B A Ponder
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

10.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Authors:  Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.